platelet response to thrombin. 8 PAR-4 is the predominant thrombin receptor in rodent platelets 15 but is also expressed in human vascular SMCs. 16 Unlike other PARs, PAR-4 is upregulated in high-glucose-stimulated SMCs. 17 Enhanced PAR-4 sensitivity was also reported in platelets from type 1 diabetic mice, 18 associated with increased susceptibility to arterial thrombosis. Whether PAR-4 also contributes to proliferative vessel remodeling, particularly in settings of diabetes mellitus, is not known. PAR-4 upregulation is partially mediated via protein kinase C isoforms (β and δ) and the transcription factor nuclear factor-κB. 17 Posttranscriptional modification of PAR- 4 has not yet been described. A candidate regulator is the mRNA stabilizing factor HuR (human antigen R, ELAV1), which is activated by protein kinase C-δ and angiotensin II, 19 and is highly abundant in human vessels with neointimal hyperplasia, atherosclerosis, or restenosis. 20 We now report increased PAR-4 expression in aorta and carotid arteries of streptozotocin (STZ)-diabetic C57Bl/6 mice, which also develop a greater degree of neointima formation after coronary artery ligation than nondiabetic mice. The augmented remodeling response is absent in diabetic mice deficient in PAR-4. At the cellular level, glucose-stimulated PAR-4 expression was found to be critically dependent on HuR-mediated mRNA stabilization. These findings, together with a high PAR-4 abundance observed in diabetic versus nondiabetic human atherectomy and a saphenous vein specimen, highlight PAR-4 as an important glucose-regulated thrombin receptor in both mice and humans with a hitherto unsuspected role in the vascular complications of diabetes mellitus.
Materials and Methods

Human Tissue Samples
Human atherectomy samples were obtained from diabetic and nondiabetic patients of both sexes presenting for carotid endarterectomy (ethics approval No. 3944). Patient characteristics are given in Table  I (in the online-only Data Supplement). Human saphenous vein segments were obtained from type 2 diabetic and nondiabetic patients presenting for coronary artery bypass grafting (ethics approval No. 3199). Donors gave informed consent. Patient characteristics are provided in Tables I-V in the online-only Data Supplement.
Immunohistochemistry of Human Tissue Sections
Paraffin sections (3 μm) were stained for PAR-4 (ab66103, 1:50; Abcam, Cambridge, United Kingdom) or anti-α smooth muscle actin (αSMA; M0851, 1:200; Dako, Glostrup, Denmark). Nuclear staining used Roti-Mount FluorCare 4',6-diamidino-2-phenylindole (Roth GmbH, Karlsruhe, Germany). Fluorescence images were captured with an AxioCam HRC camera and AxioVision Software connected to an Axio Imager.M2 microscope (Carl Zeiss, Göttingen, Germany). As negative controls, parallel sections were incubated without primary antibody; these were all negative for PAR-4 and αSMA. Mean PAR-4 fluorescence intensity was quantified using the Zeiss Zen lite 2102 Software. The atherectomy specimens contained large amounts of plaque and variable amounts of the tunica media. To define the tunica media in atherectomies, the combination of autofluorescence of elastic lamellae, presence of variable amounts of αSMA-positive SMCs, and the relative absence of collagen deposition determined by Sirius red staining was used. Representative images of the atherectomies are shown in Figures I and II in the online-only Data Supplement. The tunica media of saphenous vein sections was defined by morphology, αSMA staining, and autofluorescence (green) of elastin lamellae ( Figure III in the online-only Data Supplement).
Western Blot Analysis of PAR-4
Tissue samples (200 mg) were lysed in 500 μL of modified radioimmunoprecipitation assay buffer, followed by centrifugation and homogenization. Lysates (20 μg of protein) were separated by electrophoresis through a 12% SDS-PAGE, transferred onto nitrocellulose membrane, and probed with goat polyclonal PAR-4 (C-20) antibody (1:200, sc-8464; Santa Cruz Biotechnology, Dallas TX) or rabbit polyclonal αSMA (1:1000, ab5694; Abcam). Protein expression was normalized to β-tubulin I (1:10 000, T7816; Sigma-Aldrich, St Louis, MO).
Protein expression in cultured human vascular SMCs was detected in whole cell lysates by Western blotting as described, 21 using HuR (3A2, sc-5261) and PAR-4 (sc-8464) and normalized to β-actin. 21 Infrared fluorescent-coupled secondary antibodies were used, allowing fluorescent detection on a LI-COR Odyssey infrared imaging system.
Cell Culture
Human saphenous vein SMCs were cultured in DMEM containing 5.5 mmol/L d-glucose and 15% FCS (GibcoBRL, Rockville, MD), as described. 21 SMCs (passages 5-8) were serum deprived for 48 hours before stimulation.
PAR-4 Immunofluorescence
PAR-4 immunofluorescence (sc-8461, 1:50; Santa Cruz Biotechnology) was assessed in human vascular SMCs after preincubation with the protein kinase A (PKA) inhibitors myr-PKI and Rp-8-CPT-cAMPS for 30 minutes and stimulation with high glucose or cicaprost for 48 hours. Fluorescence images were captured with an AxioCam HRC camera and AxioVision Software connected to an Axio Imager.M2 microscope (Carl Zeiss).
Mice and STZ-Diabetes Model
Detailed procedures are outlined in the online-only Data Supplement. This study has the approval of the local animal experimentation ethics committee (Landesamt für Natur, Umwelt und Verbraucherschutz NRW, approval 87-51.04.2011.A055). PAR-4 -/-mice (C57BL/6 background) 22 were generously provided by Dr Justin Hamilton (Australian Center for Blood Diseases, Monash University, Melbourne, Victoria, Australia) and bred in-house. Type 1 diabetes mellitus was induced with a 180 mg/kg IP bolus of STZ 23 ; control mice received an equal volume of citrate buffer solvent. Nonfasted blood glucose levels 3 weeks after injection were 400 to 500 mg/dL and 150 to 250 mg/ dL, respectively, for diabetic and nondiabetic mice, regardless of genotype. Pancreatic insulin content was determined by immunohistochemistry as detailed in the online-only Data Supplement. The development of ketoacidosis was monitored using Combur 9 urinary analysis test strips (Roche-Diagnostics, Mannheim, Germany) and by mass spectrometry analysis of urinary β-hydroxybutyrate.
Carotid Artery Ligation
Ligation of the left carotid artery was performed 3 weeks after treatment with STZ or citrate solvent, as described by Kumar and Lindner. 24 Mice were anaesthetized with ketamine/xylazine (100 mg/ kg per 5 mg/kg IP). Postoperative analgesia was assured with carprofen 5 mg/kg SC. Animals were anesthetized as above 4 weeks after surgery and killed by perfusion with 4% paraformaldehyde. Paraffinembedded carotid arteries were serially sectioned (5 μm) over 1000 μm proximal to the ligation site, stained with hematoxylin-eosin, and neointimal, medial, and lumen areas were quantified by histomorphometry. Infiltrating macrophages were visualized with Mac-2 primary antibody (CL8942AP, 1:50; Cedarlane Laboratories, Burlington, Ontario, Canada) and goat anti-rat (112-295-167; Dianova, Hamburg, Germany) secondary antibody by immunofluorescence, as detailed above. For analysis of proliferating cells, mice were treated with bromodeoxyuridine (BrdU; 50 mg/kg IP) 24 
Results
Increased PAR-4 in Diabetic Human Atherectomy and Saphenous Vein Specimen
We previously reported upregulation of PAR-4 by high glucose in SMCs cultured from the human coronary artery and saphenous vein. 17 Immunohistochemical staining of PAR-4 revealed expression in the tunica media of atherectomy specimens, strongly suggesting expression in SMCs. In addition, PAR-4 staining was evident in the plaque neointima. Consecutive sections stained for αSMA suggested that the expression of PAR-4 in the media occurred mainly in SMCs with low or absent expression of αSMA ( Figure Figure 1F ). The area of the media that was included in the analysis was similar between diabetic and nondiabetic samples ( Figure IIE in the online-only Data Supplement), proving that upregulation of PAR-4 is not simply a reflection of increased amounts of medial tissue in the diabetic group. Similarly, total PAR-4 protein expression in atherectomies, as determined by Western blotting, was increased ( Figure 1H ; PAR-4, 2.261±0.500-fold of nondiabetic; n=12). Increased PAR-4 was also observed in human coronary artery samples from diabetic versus nondiabetic patients (n=3 each; Figure  IV in the online-only Data Supplement). In addition to immunohistochemistry and immunoblotting, real-time polymerase chain reaction also revealed increased PAR-4 mRNA expression in diabetic atherectomy samples, by ≈9-fold compared with nondiabetic samples ( Figure 1G ; P<0.05; n=12, n=15).
PAR-4 abundance was also examined in nondiabetic (n=9) versus diabetic (n=9) human saphenous veins ( Figure 2A versus Figure 2B ). As indicated by morphology and αSMA staining, PAR-4 expression occurred mainly in the media (Figure 2A through 2D). Interestingly, although PAR-4 expression was also localized to areas of αSMA-positive SMCs in the media, the staining revealed that PAR-4 was expressed more strongly in the luminal parts of the media and to a lesser degree in the abluminal part of the media where marked expression of αSMA occurred. Therefore, similar to atherectomies, in veins the expression of PAR-4 might also be attributed to the more dedifferentiated SMC phenotype. Importantly, mean PAR-4 immunofluorescence intensities in the media of nondiabetic and diabetic veins were 223.40±8.13 and 272.00±17.00, respectively, corresponding with an increase of ≈22% in diabetic human saphenous veins ( Figure 2E ). PAR-4 mRNA expression was increased to ≈19-fold in diabetic versus nondiabetic human saphenous veins ( Figure 2F ; n=6, n=10; P<0.05). Given the stronger PAR-4 mRNA induction in diabetic veins compared with atherectomies, subsequent in vitro studies examining the mechanisms of glucose-regulated PAR-4 expression were performed in human saphenous vein SMCs.
PAR-4 Upregulation by High Glucose Requires HuR-Mediated Transcript Stabilization
To gain further insights into the mechanisms that mediate the increased PAR-4 expression in diabetic vessels, the possible contribution of mRNA stabilization by HuR was investigated. Nucleocytosolic shuttling of HuR is a prerequisite for its mRNAstabilizing activity and was determined by immunofluorescence in high-glucose-treated SMCs. A time-dependent cytosolic HuR accumulation was maximal at 3 hours ( Figure 3A ; n=5). Similar results were obtained by Western blotting (Figure 3B ; n=5; P<0.05). Total HuR protein expression did not change over time ( Figure 3B ), nor did high glucose influence HuR mRNA expression over 24 hours (data not shown; n=4). HuR small interfering RNA prevented the stimulatory effects of high glucose (6 hours) on PAR-4 mRNA expression ( Figure 3C ; n=5). 
Downregulation of PAR-4 Expression by Agents That Elevate cAMP
cAMP blocks HuR activation in human vascular SMCs. 21 In the present study, basal PAR-4 mRNA expression was suppressed in a time-dependent manner by the adenylate cyclase activator forskolin (10 μmol/L), by the chemically stable prostaglandin I 2 analogue cicaprost (10 nmol/L), and by exogenous prostaglandin E 2 (1 μmol/L; all n=4; Figure 4A ). Cicaprost also accelerated the decay of the PAR-4 transcript in the presence of actinomycin D (Figure 4B ; n=4) and counteracted high-glucose-stimulated accumulation of HuR-bound PAR-4 mRNA (3-hour incubation; Figure 4C ; all n=3). HuR nucleocytosolic shuttling was suppressed by cicaprost with no change in total cellular HuR protein ( Figure 4D online-only Data Supplement; n=5). Suppression by cicaprost was similar when cicaprost was added together with high glucose for 48 hours or only for the final 24 hours of incubation. Cicaprost also blunted basal and thrombin (3 U/mL)-evoked tumor necrosis factor-α mRNA expression in high-glucosetreated SMCs (Figure 4F; n=4; P<0.05) .
The contributions of the cAMP effector protein kinase A and the exchange protein directly activated by cAMP (Epac) were subsequently assessed. An Epac activator (8-pCPT-2′-O-Me-cAMP) did not influence PAR-4 expression (data not shown). However, 2 different PKA inhibitors (and Rp-8-CPTcAMPS) counteracted the effects of cicaprost in high-glucosestimulated cells. In the absence of PKA inhibition, cicaprost suppressed nucleocytosolic shuttling of HuR in response to high glucose; the addition of a PKA inhibitor or Rp-8-CPTcAMPS restored HuR translocation (Figure 5A and 5B; n=4). Accordingly, high-glucose-stimulated increases in PAR-4 immunofluorescence were abolished by cicaprost and restored in the presence of a PKA inhibitor (Figure 5C and 5D; n=3) .
Systemic Hyperglycemia in STZ-Treated Mice Increases Vascular PAR-4
The functional significance of PAR-4 upregulation was examined in a mouse model of type 1 diabetes mellitus. Three weeks after treatment of male C57BL/6 mice with STZ, blood glucose levels were increased to >400 mg/dL versus 200 mg/dL (Figure 6A ; n=4; P<0.05), whereas insulin immunoreactivity in pancreatic islets was reduced compared with solvent-treated controls ( Figure VIIIA in the online-only Data Supplement; n=4). Vascular PAR-4 mRNA expression was significantly increased after 3 weeks in aortas from diabetic mice to 9.0±1.5-fold of nondiabetic controls (Figure 6B ; n=4; P<0.05), as was PAR-4 immunofluorescence in both the aorta ( Figure 6C and 6D ) and left carotid artery (Figure 6E and 6F ; all n=4). PAR-4 expression levels did not differ between the groups at earlier time points (data not shown). Aortic PAR-1 expression was not significantly altered in diabetic versus nondiabetic mice (Figure VIIIB in the online-only Data Supplement; n=4).
PAR-4 Deficiency Protects Against Augmented Neointimal Hyperplasia in Diabetic Mice
Left carotid arteries were ligated 3 weeks after STZ or citrate treatment and collected for analysis 4 weeks after surgery. Wild-type STZ-diabetic mice exhibited dramatically augmented neointimal thickening, which was completely absent in PAR-4 -/-diabetic mice. Neointima formation in nondiabetic PAR-4 -/-mice was comparable to the wild-type control Figure 7A through 7D. Pooled area quantifications >1000 μm for nondiabetic and diabetic mice, respectively, are shown in Figure 7E and 7F, and neointima/media ratios across all sections to 1000 μm proximal to the ligation site are depicted in Figure 7G (all n=6). Nonligated right carotid arteries showed no neointimal thickening ( Figure IX in the online-only Data Supplement; n=6). Unlike the neointimal area, neither the medial nor lumen areas differed significantly between the groups (Figure X in the online-only Data Supplement). Furthermore, the intimal cell density was not different between diabetic wild-type and diabetic PAR-4 -/-mice, indicating a proportional decrease of cell numbers and matrix (data not shown). β-Hydroxybutyrate was determined by mass spectroscopy in the urine to control for ketoacidosis. This measurement showed a trend to increased concentrations of β-hydroxybutyrate in diabetic mice but no differences between wild-types and PAR-4 -/-mice. The average β-hydroxybutyrate concentration in the urine of diabetic mice was in the range of 20 mg/g of creatinine (data not shown), which is well below the threshold of ketoacidosis. Therefore, it is concluded that the observed protection against neointimal hyperplasia after the deletion of PAR-4 is independent of ketoacidosis.
Increased Proliferation in Ligated Carotid Arteries
In parallel with quantification of the neointimal area in left carotid arteries, proliferative responses attributed to arterial injury were assessed 7 days after ligation by determining BrdU incorporation. Tissue sections were obtained 50 μm proximal to the ligation site, at which point the degree of neointima formation was comparable across all of the experimental groups. Representative images are depicted in Figure 8A through 8D. Quantification of BrdU-positive cells, normalized to total neointimal cells, is shown in Figure 8E . The proliferating cell count was significantly higher in diabetic versus nondiabetic wild-type mice (nondiabetic wild-type, 3.0±0.9% BrdU-positive cells per total intimal cells versus diabetic wildtype, 9.8±1.3% BrdU-positive cells per total intimal cells; n=6.5), whereas no such increase was observed in mice lacking PAR-4. A significant decrease of the proliferation index was apparent between wild-type diabetic mice and PAR4-deficient diabetic mice ( Figure 8E ; n=6 for wild-type controls; n=5 for all other groups). As a measure of inflammatory cell accumulation, Mac-2-positive cell counts were normalized to total cell content within the neointimal area ( Figure XI in the online-only Data Supplement; n=6 for wild-type controls; n=5 for all other groups). Wild-type diabetic mice exhibited significantly higher numbers of Mac-2-positive cells than nondiabetic mice, whereas no such increase was observed in PAR-4-deficient animals.
Discussion
The present study identifies PAR-4 as a novel mediator linking hyperglycemia, hypercoagulation, and vascular remodeling in diabetes mellitus. Diabetic patients are particularly prone to thrombotic and proliferative vessel occlusion, 1, 2 in which thrombin plays a key role. Although much attention has focused on inhibiting PAR-1, the classic thrombin receptor, 5, 9, 11, 25 the contribution of PAR-4 has been largely underestimated. We now report increased PAR-4 expression in atherectomy and saphenous vein samples from patients with diabetes mellitus, in keeping with our previous report that high glucose upregulates PAR-4 in human vascular SMCs.
In diabetic human atherectomy samples, increased PAR-4 abundance was observed in the tunica media, as indicated by immunofluorescence, Western blotting, and mRNA expression. In contrast, no difference in expression between nondiabetic and diabetic was detected in the neointima. Medial areas were equivalent, confirming that the increase in PAR-4 expression is not merely because of increased amounts of medial tissue in diabetic atherectomies. PAR-4 immunofluorescence was detected mainly in areas of the media with low expression of αSMA. These data are suggestive of PAR-4 expression in dedifferentiated SMCs and, to a lesser degree, in differentiated SMCs. This hypothesis is in line with the marked upregulation of PAR-4 in response to high glucose in cultured vascular SMCs that also represent the dedifferentiated phenotype. However, it cannot be excluded that other cells also express PAR-4 in human atherectomies. The increased expression of PAR-4 in the tunica media is consistent with a role of PAR-4 in initiating the migration and proliferation of medial SMCs. Human saphenous veins show a greater difference between nondiabetic and diabetic PAR-4 mRNA abundance (≈19-fold difference) than atherectomies. Although diabetes mellitus is not associated with increased rates of venous disease, it is associated with increased rates of vein closure after bypass grafting. 1, 2 Potentially the strong induction in diabetic veins contributes to the enhanced proliferative remodeling and, hence, reduced graft patency reported in patients with diabetes mellitus. Compared with nondiabetic saphenous veins, diabetic veins express ≈19-fold more PAR-4 mRNA and exhibit a 22% greater PAR-4 immunoreactivity. Human diabetic atherectomies express ≈9-fold more PAR-4 mRNA and exhibit a 23% greater PAR-4 immunoreactivity than nondiabetic samples. The reasons for the differing magnitude of mRNA and protein induction in the specimens are not clear. In isolated SMCs, high glucose increases PAR-4 expression by ≈3-fold at the mRNA level and 2-fold at the cell surface, similarly to our findings with activated factor X-stimulated PAR-2 expression. 26 In the present in situ study, the difference in expression is greater, and changes in mRNA levels do not correspond 1:1 with changes in protein. Whether this is the result of differences in translation efficiency, protein degradation, or efficiency of shuttling to the cell surface is not known.
Given the strong PAR-4 upregulation in venous vessels, the cellular pathways underlying PAR-4 regulation were further explored in SMCs cultured from human saphenous vein. Transcript stabilization is a major mechanism of posttranscriptional gene regulation, particularly of inducible genes. 19, 27 HuR, or ELAV1, the most characterized of a number of mRNA stabilizing proteins, 19, 27 shows particularly high abundance in human atherosclerosis, intimal hyperplasia, and sclerosed saphenous vein grafts. 20 We now show that high glucose promotes HuR translocation in human vascular SMCs and augments cytosolic accumulation of HuR-bound PAR-4 mRNA, whereas HuR small interfering RNA abolishes high-glucose-induced PAR-4 expression. Accordingly, PAR-4 mRNA decay in the presence of the transcription inhibitor actinomycin D is slowed in highglucose-treated SMCs, and maximal stabilization is seen at showed multiple adenylate-uridylate-rich elements that could serve as HuR binding motifs, whereas no such motifs can be found in the PAR-1 sequence. Accordingly, PAR-1 mRNA is not stabilized by high glucose. In our supplementary data, we show that angiotensin II, a classic activator of HuR, 19 transiently upregulates PAR-4 mRNA and protein in an HuR-dependent manner, with no effect on PAR-1. HuR shuttling is also shown to be activated in response to H 2 O 2 ; accordingly, inhibition of NADPH oxidase with apolipoprotein/diphenylene iodonium to block H 2 O 2 production or catalase, which degrades H 2 O 2 , prevents high-glucose-stimulated PAR-4 induction in human vascular cells.
A further candidate regulator of PAR-4 is cAMP, which attenuates the mRNA stabilizing activity of HuR in human vascular SMCs. 21 Several cAMP stimuli, including forskolin, the prostacyclin analogue cicaprost, and exogenous prostaglandin E 2 , reduce basal PAR-4 mRNA expression in the present study. Cicaprost moreover accelerates PAR-4 mRNA decay in human SMCs. This destabilizing action can be attributed to impaired HuR/PAR-4 mRNA binding and nucleocytosolic shuttling in the presence of the prostacyclin analogue. As a consequence, cicaprost normalizes PAR-4 expression in high-glucose-treated SMCs, both when added concurrently with high glucose for 48 hours or only for the final 24 hours of incubation, and thrombin-stimulated expression of the inflammatory cytokine tumor necrosis factor-α is blunted. Thus, prostacyclin might limit proliferative and inflammatory processes in the vessel wall, both through its direct antitrophic, antithrombotic, and antiadhesive effects 28 and indirectly by suppressing PAR-4. Venous vessels, which are particularly prone to restenosis, exhibit an impaired capacity to generate prostacyclin compared with arteries, 29 and a lower level of endogenous prostacyclin production could explain the stronger PAR-4 immunoreactivity detected in human saphenous veins compared with atherectomy samples.
The precise mechanism by which cAMP suppresses HuRmediated stabilization of PAR-4 mRNA remains to be defined. cAMP has been reported to downregulate soluble guanylate cyclase by suppressing HuR expression. 30 This effect was, however, evident over 4 to 12 hours, whereas in our study, the destabilizing effects of the cAMP activator cicaprost are observed within 1 to 2 hours, as is inhibition of HuR shuttling, whereas total HuR expression is unaltered. Similarly, the stimulatory effects of high glucose on HuR shuttling and PAR-4 mRNA stability occur within 1 to 3 hours, also with no change in total HuR abundance. Thus, HuR downregulation is not likely to be involved in cAMP-regulated PAR-4 expression, nor does the cAMP effector Epac appear to contribute. Phosphorylation is the primary mechanism by which the nucleocytosolic translocation of HuR is controlled, 31 and although the cAMP effector PKA has not specifically been reported to phosphorylate HuR, its phosphorylation substrates include a number of proteins in the 35-to 52-kDa range, 32 which encompasses HuR. We find that inhibition of PKA abolishes the ability of cicaprost to counteract high-glucose-stimulated HuR shuttling in human vascular SMCs; accordingly, high-glucose-stimulated PAR-4 expression is also restored in cicaprost-treated cells on the addition of PKA inhibitors.
PAR-4 contributes to thrombin-stimulated vascular SMC mitogenesis, migration, and inflammatory gene expression. 16, 17 Moreover, PAR-4 is also activated by cathepsin G, an elastase released by neutrophils, which accumulate in diabetic tissues and contribute to neointimal hyperplasia. 33 Thus, glucose-regulated PAR-4 expression might be important for accelerated vascular remodeling in diabetes mellitus. 1 In this proof-of-concept study, we show for the first time that PAR-4 deficiency protects against the enhanced neointimal hyperplasia that develops in STZ-diabetic mice after carotid artery ligation. STZ-treated mice exhibited marked hyperglycemia but no evidence of ketoacidosis 3 weeks after the induction of diabetes mellitus; the increase in blood glucose was accompanied by a time-dependent increase in PAR-4 (but not PAR-1) expression in both the aorta and carotid arteries. To test the potential consequences for vascular remodeling, the left carotid artery was ligated according to a conventionally established model of neointimal thickening. 24 Diabetic mice are shown to develop greater neointima formation than nondiabetic mice, mirroring an earlier report. 34 In that study, oxidative stress, which we here show to posttranscriptionally regulate PAR-4, was found to contribute to the augmented neointima formation. Diabetic mice deficient in PAR-4 showed no such augmented remodeling response; in fact, the neointimal area was smaller even than in nondiabetic wild-type mice. The reasons for this more-than-complete suppression are not clear. Neointima formation in nondiabetic PAR-4 -/-mice was comparable to the wild-type controls, suggesting that the involvement of PAR-4 under normoglycemic conditions is negligible.
In an effort to understand why PAR-4 deficiency protects against excessive vessel remodeling in diabetic mice, the impact on macrophage accumulation and on proliferating cell numbers was assessed. Arterial wall injury is associated with the recruitment of inflammatory cells, specifically circulating monocytes, which differentiate into macrophages and actively contribute to neointimal hyperplasia. 35 Thrombin and its prototypical receptor PAR-1 have been identified as critical players in this process. 36 In this study, carotid arteries from diabetic mice show a greater accumulation of macrophages 7 days after ligation than control mice, whereas no such increase is observed in arteries from PAR-4 -/-mice. Similarly, the proportion of BrdU-labeled cells, determined as a measure of proliferation 7 days after ligation, is significantly higher in diabetic wild-type mice compared with nondiabetic controls and diabetic PAR-4-deficient mice. Therefore, the augmented neointimal hyperplasia in diabetic animals can mainly be attributed to a greater degree of proliferation resulting from increased expression of PAR-4.
In conclusion, PAR-4 shows increased expression in diabetic human and murine vessels, and PAR-4 deficiency protects against the excessive remodeling induced by carotid artery ligation. At the cellular level, PAR-4 abundance is critically controlled via the mRNA stabilizing actions of HuR, which account for the stimulatory actions of high glucose, angiotensin II, and H 2 O 2 on PAR-4 expression, whereas cAMP agonists, such as the prostacyclin analogue cicaprost, counteract this effect. Such interactions could potentially represent a fine-tuning mechanism to control PAR-4 expression and ultimately also the mitogenic actions of thrombin in the diabetic vessel wall. PAR-4 might potentially serve as a suitable therapeutic target to limit proliferative and inflammatory processes in restenosis-prone diabetic patients, particularly those patients in whom severe bleeding because of selective PAR-1 blockade or complete thrombin inhibition must be avoided or who do not require anticoagulation.
